Madrigal Pharmaceuticals (MDGL) vs Recursion Pharmaceuticals (RXRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 11, 2026.
Summary
Madrigal Pharmaceuticals (MDGL) has outperformed Recursion Pharmaceuticals (RXRX) over the past year, gaining 9.8% versus a loss of 18.0%. Over five years, MDGL leads with a +447.5% price change compared with -77.1% for RXRX. Madrigal Pharmaceuticals is the larger company by market cap ($10.90 billion vs $2.34 billion), about 4.7 times the size.
Madrigal Pharmaceuticals converts more of its revenue into profit, with a net margin of -30.1% versus -863.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MDGL | RXRX |
|---|---|---|
| Share price | $471.75 | $4.36 |
| Market cap | $10.90B | $2.34B |
| 1-day change | -1.08% | +10.38% |
| YTD return | -18.99% | +6.60% |
| 1-year return | +9.81% | -18.05% |
| 5-year return | +447.46% | -77.10% |
| Forward P/E | 49.01 | — |
| EPS (TTM) | $-12.85 | $-1.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $958.40M | $74.68M |
| Revenue growth (YoY) | +432.05% | +26.92% |
| Net income (latest FY) | $-288.28M | $-644.76M |
| Gross margin | — | 4.99% |
| Operating margin | -31.31% | -867.87% |
| Net margin | -30.08% | -863.35% |
| 52-week high | $615.00 | $7.18 |
| 52-week low | $393.61 | $2.77 |
| Distance from 52-week high | -23.29% | -39.28% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +44.59% | +65.60% |
| Average volume | 289.54K | 20.93M |
| Shares outstanding | 23.10M | 535.34M |
| Employees | 915 | 600 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Madrigal Pharmaceuticals is about 4.7 times larger than Recursion Pharmaceuticals by market value ($10.90B vs $2.34B).
- MDGL has outperformed RXRX by 27.9 percentage points over the past year.
- Madrigal Pharmaceuticals is more profitable, keeping -30.1 cents of every revenue dollar as net income versus -863.4 cents for Recursion Pharmaceuticals.
- Madrigal Pharmaceuticals grew revenue faster in its latest fiscal year (+432.05% vs +26.92%).
About Madrigal Pharmaceuticals
MDGL stock →Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH.
Health Care · Biotechnology: Pharmaceutical Preparations · 915 employees
About Recursion Pharmaceuticals
RXRX stock →Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 600 employees
MDGL vs RXRX FAQ
Which is bigger, Madrigal Pharmaceuticals or Recursion Pharmaceuticals?
Madrigal Pharmaceuticals (MDGL) is larger, with a market capitalization of $10.90B compared with $2.34B for Recursion Pharmaceuticals (RXRX).
Which stock has performed better over the past year, MDGL or RXRX?
MDGL returned +9.81% over the past 12 months, compared with -18.05% for RXRX (price return, excluding dividends). Past performance does not predict future results.
Are Madrigal Pharmaceuticals and Recursion Pharmaceuticals in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Madrigal Pharmaceuticals and Biotechnology: Biological Products (No Diagnostic Substances) for Recursion Pharmaceuticals.